ClinicalTrials.gg
CompletedNCT00083720Updated May 25, 2011Results posted

Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

A Phase 2 interventional study of cetuximab in Colorectal Neoplasms, Metastases and Neoplasm, sponsored by Eli Lilly and Company. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-25.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
76th of 185
87 · median 60
Started
2004
with 9 others
Phase 2
107 of 187
20 open now
Registered
11th of 187
by date
Lead sponsor
7 of 187
Eli Lilly and Company

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 76th largest by enrollment of the 185 interventional ones that give a count, is one of 10 that started in 2004, is one of 107 in phase 2, and was the 11th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a phase II, multicenter, open-label study of cetuximab in patients with epidermal growth factor receptor (EGFR) negative, metastatic colorectal carcinoma who have progressed after receiving at least one standard chemotherapeutic regimen that included a fluoropyrimidine. Target enrollment is 80 evaluable patients.

Patients with EGFR-negative metastatic colorectal carcinoma who have progressed after receiving at least one standard chemotherapeutic regimen that included a fluoropyrimidine, will receive an initial dose of cetuximab, 400 mg/m2 , intravenously (i.v.) over 120 minutes, followed by weekly treatment with cetuximab, 250 mg/m2 i.v. over 60 minutes. Patients who experience unacceptable toxicity or who have progressive disease (PD) will not receive further cetuximab therapy.

Patients will be evaluated for a tumor response at a minimum of every 6 weeks while on cetuximab therapy. Patients with stable disease (SD), partial response (PR), or a complete response (CR) may continue to receive weekly cetuximab therapy, unless they are dose-delayed or discontinued because of toxicity. Patients who have a PR or CR must have a confirmatory tumor assessment no less than 4 weeks after the initial evaluation demonstrating a response. To evaluate the objective response rate, a single-stage design will be used in this study.

03

Conditions studied

  • Colorectal Neoplasms
  • Metastases
  • Neoplasm

Keywords

  • EGFR-undetectable
  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provided signed written .
  • - or pathologically- confirmed colorectal carcinoma;
  • Documented PD after treatment with at least one standard chemotherapy regimen for metastatic colorectal carcinoma;
  • The chemotherapy regimen on which the patient progressed, must have included a fluoropyrimidine;
  • Bidimensionally ;
  • Immunohistochemical evidence of an absence of EGFR expression, (ie, EGFR-negative). Patients who do not have tumor tissue available for EGFR testing will undergo of accessible tumor. A reference laboratory designated by ImClone will perform the EGFR assay.
  • (ECOG) performance status score of 0 to 1 at study entry;
  • Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least 30 days must have elapsed from major surgery, prior chemotherapy, prior treatment with an agent or medical device, or prior radiation therapy;
  • Accessible for treatment and follow-up. Patients enrolled in this trial must be treated at the participating center.
  • Men and women, 18 years of age and older

Exclusion criteria

Exclusion Criteria:

  • Women of child bearing potential () who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study.
  • Women who are pregnant or breastfeeding.
  • Women with a positive pregnancy test on enrollment or prior to cetuximab administration.
  • Sexually active fertile men not using effective .
  • Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of ;
  • A serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy;
  • A history of uncontrolled angina, arrhythmias or congestive heart failure;
  • Symptomatic or uncontrolled to the central nervous system. Patients receiving a for central nervous system (CNS) metastases will be excluded, but those receiving anticonvulsants will be eligible.
  • Any concurrent other than non-melanoma skin cancer or carcinoma in situ of the cervix. Patients with a previous malignancy but without evidence of disease for greater than or equal to 5 years will be allowed to enter the trial;
  • Inadequate hematologic function defined by an (ANC) less than 1,500/mm3 , a count less than 100,000/mm3 , or a level less than 9 g/dL.
  • Inadequate hepatic function, defined by a total level greater than or equal to 1.5 times the (ULN) and (AST) or alanine transaminase (ALT) levels greater than or equal to 5.0 times the ULN.
  • Inadequate renal function defined by a serum creatinine level greater than 1.5 times the ULN.
  • Prior cetuximab or other therapy, which specifically and directly targets the EGF pathway.
  • Prior reaction to chimerized or murine monoclonal antibody therapy.
  • Any chemotherapy not indicated in the study protocol, radiation therapy, hormonal therapy (except for physiological replacement), or any other agent.
  • Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious disease) illness.
  • Employees of the investigator or study center with direct involvement in this study or other studies under the direction of the investigator or study center, as well as family members of the employees.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    cetuximab

    Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes

    Biological: cetuximab

Interventions

  • Biologicalcetuximab

    Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes

    Also known as: Erbitux™

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Overall Resonse

    Determine the response rate (complete response \[CR\] and partial response \[PR\]) in patients with epidermal growth factor receptor (EGFR)-negative metastatic colorectal carcinoma treated with cetuximab, as classified by the investigator according to the World Health Organization (WHO) criteria. The calculation was the total number of patients with CR or PR divided by the total number of patients treated.

    Time frame: Tumor evaluations were performed at a minimum every 6 weeks while on cetuximab therapy until progressive disease (PD) or recurrence. Patients with a PR or CR had a confirmatory tumor assessment no less than 4 weeks after the initial evaluation.

  2. Number of Participants With Adverse Events

    Reported adverse events (AEs) per patient were coded according to the corresponding preferred term and system organ class in the Medical Dictionary for Regulatory Activities dictionary. The National Cancer Insititute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0 was used to grade all AEs. The collection of AEs began at the time the patient received the first cetuximab dose and continued during the study until 30 days after the last dose of cetuximab. All patients who were enrolled and treated with cetuximab were assessed for safety (mITT population, as treated).

    Time frame: An adverse event (AE) was included in the safety analysis if its onset date occurred anytime during cetuximab treatment or up to 30 days after the last dose of cetuximab.

  3. Number of Participants With Serious Adverse Events

    Reported SAEs per patient were coded according to the corresponding preferred term and system organ class in the Medical Dictionary for Regulatory Activities. The NCI-CTCAE Version 3.0 was used to grade all SAEs. An SAE was any untoward medical occurrence that resulted in death, persistent/significant disability/incapacity, was life threatening, required inpatient hospitalization or caused prolongation of existing hospitalization,congenital anomaly/birth defect, or any important medical event.

    Time frame: A serious adverse event (SAE) was included in the safety analysis if its onset date occurred anytime during cetuximab treatment or up to 30 days after the last dose of cetuximab.

Secondary outcomes

  1. Percentage of Participants With Disease Control (CR, PR, or SD)

    This is the total number of patients with a best overall response of CR, PR, and stable disease (SD) divided by the total number of patients treated.

    Time frame: Tumor evaluations were performed at a minimum of every 6 weeks while on cetuximab therapy. Patients with a PR or CR had a confirmatory tumor assessment no less than 4 weeks after the initial evaluation demonstrating a response.

  2. Duration of Response

    In patients with a best overall response of CR or PR, the duration of response is measured from the date criteria are first met for CR or PR, until the first date that Progressive Disease (PD) is objectively documented or death occurs. Duration of response of living patients with no evidence of PD was censored on the date of their last tumor assessment.

    Time frame: The duration of response was measured from the date of response to the first date of PD (range 2 to 7 months).

  3. Time to Progression

    This measure was defined as the time from the first day of treatment until the date of PD. Deaths without objective progression were censored. Patients who did not progress were censored at their last day of tumor assessment.

    Time frame: Patients with PD after receiving at least one standard chemotherapeutic regimen that included a fluoropyrimidine (range: 1-3 months).

  4. Overall Survival

    This measure is defined as the time from the first day of therapy to the date of death. Survival of living patients or those lost to follow-up were censored on the last date the patients were known to be alive.

    Time frame: Survival information was collected every 3 months after completion of therapy and/or follow-up up to 24 months.

07

Results

Posted Oct 23, 2009

Participant flow

A total of 87 patients were enrolled between 22 Oct 2004 and 20 Aug 2007 at nine sites in the USA and four sites in Canada.

Participant flow — Overall Study
MilestoneCetuximab
Started85
Completed85
Not completed0

Outcome measures

PrimaryPercentage of Participants With an Overall Resonse

Determine the response rate (complete response \[CR\] and partial response \[PR\]) in patients with epidermal growth factor receptor (EGFR)-negative metastatic colorectal carcinoma treated with cetuximab, as classified by the investigator according to the World Health Organization (WHO) criteria. The calculation was the total number of patients with CR or PR divided by the total number of patients treated.

Time frame:
Tumor evaluations were performed at a minimum every 6 weeks while on cetuximab therapy until progressive disease (PD) or recurrence. Patients with a PR or CR had a confirmatory tumor assessment no less than 4 weeks after the initial evaluation.
Reported as:
Mean · percentage of participants
Percentage of Participants With an Overall Resonse
percentage of participantsCetuximab
Percentage of Participants With an Overall Resonse8.2 (3.4 to 16.2)
SecondaryPercentage of Participants With Disease Control (CR, PR, or SD)

This is the total number of patients with a best overall response of CR, PR, and stable disease (SD) divided by the total number of patients treated.

Time frame:
Tumor evaluations were performed at a minimum of every 6 weeks while on cetuximab therapy. Patients with a PR or CR had a confirmatory tumor assessment no less than 4 weeks after the initial evaluation demonstrating a response.
Reported as:
Mean · Percentage of participants
Percentage of Participants With Disease Control (CR, PR, or SD)
Percentage of participantsCetuximab
Percentage of Participants With Disease Control (CR, PR, or SD)49.4 (38.4 to 60.5)
SecondaryDuration of Response

In patients with a best overall response of CR or PR, the duration of response is measured from the date criteria are first met for CR or PR, until the first date that Progressive Disease (PD) is objectively documented or death occurs. Duration of response of living patients with no evidence of PD was censored on the date of their last tumor assessment.

Time frame:
The duration of response was measured from the date of response to the first date of PD (range 2 to 7 months).
Reported as:
Median · Months
Duration of Response
MonthsCetuximab
Duration of Response5.1 (2.7 to 6.9)
SecondaryTime to Progression

This measure was defined as the time from the first day of treatment until the date of PD. Deaths without objective progression were censored. Patients who did not progress were censored at their last day of tumor assessment.

Time frame:
Patients with PD after receiving at least one standard chemotherapeutic regimen that included a fluoropyrimidine (range: 1-3 months).
Reported as:
Median · Months
Time to Progression
MonthsCetuximab
Time to Progression2.5 (1.3 to 2.8)
SecondaryOverall Survival

This measure is defined as the time from the first day of therapy to the date of death. Survival of living patients or those lost to follow-up were censored on the last date the patients were known to be alive.

Time frame:
Survival information was collected every 3 months after completion of therapy and/or follow-up up to 24 months.
Reported as:
Median · Months
Overall Survival
MonthsCetuximab
Overall Survival10.0 (7.5 to 12.0)
PrimaryNumber of Participants With Adverse Events

Reported adverse events (AEs) per patient were coded according to the corresponding preferred term and system organ class in the Medical Dictionary for Regulatory Activities dictionary. The National Cancer Insititute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0 was used to grade all AEs. The collection of AEs began at the time the patient received the first cetuximab dose and continued during the study until 30 days after the last dose of cetuximab. All patients who were enrolled and treated with cetuximab were assessed for safety (mITT population, as treated).

Time frame:
An adverse event (AE) was included in the safety analysis if its onset date occurred anytime during cetuximab treatment or up to 30 days after the last dose of cetuximab.
Reported as:
Number · Participants
Number of Participants With Adverse Events
ParticipantsCetuximab
Number of Participants With Adverse Events85
PrimaryNumber of Participants With Serious Adverse Events

Reported SAEs per patient were coded according to the corresponding preferred term and system organ class in the Medical Dictionary for Regulatory Activities. The NCI-CTCAE Version 3.0 was used to grade all SAEs. An SAE was any untoward medical occurrence that resulted in death, persistent/significant disability/incapacity, was life threatening, required inpatient hospitalization or caused prolongation of existing hospitalization,congenital anomaly/birth defect, or any important medical event.

Time frame:
A serious adverse event (SAE) was included in the safety analysis if its onset date occurred anytime during cetuximab treatment or up to 30 days after the last dose of cetuximab.
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events
ParticipantsCetuximab
Number of Participants With Serious Adverse Events19

Adverse events

Collected over Adverse events were collected from the time that the patient received the initial cetuximab infusion and continued during the study until 30 days after the last dose of cetuximab.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab—19/85 (22.4%)84/85 (98.8%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventCetuximab
Disease progressionGeneral disorders3/85
DyspneaRespiratory, thoracic and mediastinal disorders3/85
DiarrheaGastrointestinal disorders1/85
Gastrointestinal haemorrhageGastrointestinal disorders1/85
Intestinal obstructionGastrointestinal disorders1/85
Small intestinal obstructionGastrointestinal disorders1/85
DeathGeneral disorders1/85
Infusion related reactionGeneral disorders1/85
PyrexiaGeneral disorders1/85
Anaphylactic reactionImmune system disorders1/85
Most frequent other events
Showing 10 of 22
Most frequent other events
EventCetuximab
Dermatitis acneiformSkin and subcutaneous tissue disorders73/85
FatigueGeneral disorders27/85
HeadacheNervous system disorders25/85
AnorexiaMetabolism and nutrition disorders20/85
Dry skinSkin and subcutaneous tissue disorders15/85
NauseaGastrointestinal disorders13/85
DiarrheaGastrointestinal disorders12/85
HypomagnesaemiaMetabolism and nutrition disorders10/85
StomatitisGastrointestinal disorders9/85
Nail disorderSkin and subcutaneous tissue disorders9/85

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cetuximab
<=18 years0
Between 18 and 65 years42
>=65 years43
Age Continuous
Age Continuous(years)Cetuximab
Mean64.2 ± 11.41
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab
Female26
Male59
Region of Enrollment
Region of Enrollment(participants)Cetuximab
United States20
Canada65
08

Study locations

27 sites
  • ImClone Investigational Site
    Campbell, California 95008, United States
  • ImClone Investigational Site
    Los Angeles, California 90033, United States
  • ImClone Investigational Site
    Soquel, California 95073, United States
  • ImClone Investigational Site
    Jacksonville, Florida 32256, United States
  • ImClone Investigational Site
    Orlando, Florida 32804, United States
  • ImClone Investigational Site
    Ormond Beach, Florida 32174, United States
  • ImClone Investigational Site
    Gurnee, Illinois 60031, United States
  • ImClone Investigational Site
    Evansville, Indiana 47714, United States
  • ImClone Investigational Site
    Indianapolis, Indiana 46202, United States
  • ImClone Investigational Site
    Lexington, Kentucky 40503, United States
  • ImClone Investigational Site
    Louisville, Kentucky 40202, United States
  • ImClone Investigational Site
    Metairie, Louisiana 70006, United States
  • ImClone Investigational Site
    Boston, Massachusetts 02114, United States
  • ImClone Investigational Site
    Ann Arbor, Michigan 48106-0995, United States
  • ImClone Investigational Site
    Kalamazoo, Michigan 49048, United States
  • ImClone Investigational Site
    St. Louis, Missouri 63110, United States
  • ImClone Investigational Site
    Armonk, New York 10504, United States
  • ImClone Investigational Site
    East Setauket, New York 11733, United States
  • ImClone Investigational Site
    Durham, North Carolina 27710, United States
  • ImClone Investigational Site
    Sellingsgrove, Pennsylvania 17870, United States
  • ImClone Investigational Site
    Arlington, Texas 76012, United States
  • ImClone Investigational Site
    Bryan, Texas 77802, United States
  • ImClone Investigational Site
    Temple, Texas 76508, United States
  • ImClone Investigational Site
    Oshawa, Ontario L1G 2B9, Canada
  • ImClone Investigational Site
    Ottawa, Ontario K1H 1C4, Canada
  • ImClone Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • ImClone Investigational Site
    Toronto, Ontario M5G 2M9, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2004
First posted
Jun 2, 2004
Start
Oct 2004
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Oct 23, 2009
Last update
May 25, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00083720
First posted
Jun 2, 2004
Start date
Oct 2004
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Oct 23, 2009
Last update
May 25, 2011

Study contacts

E-mail: ClinicalTrials@ ImClone.com
study chair · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion